Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertising
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Advisory Committees

Duchenne Group's Presentation Is Milestone For Patient Involvement

  • News

Executive Summary

Advocacy group gets portion of Sarepta's formal presentation period to present eteplirsen patient experience data, believed to be a first for an advisory committee meeting. Will it become commonplace?

Table

View full table

Advertisement

Related Content

Pink Sheet
US FDA Planning Another Patient Group To Boost Involvement
Pink Sheet
Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs
Pink Sheet
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
Pink Sheet
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Pink Sheet
US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Pink Sheet
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Pink Sheet
Patient-Driven Drug Development Requires New Transparency Policies
Pink Sheet
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Pink Sheet
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
Pink Sheet
FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical United States Advisory Committees
UsernamePublicRestriction

Register

PS057609

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By